FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2410289376> ?p ?o ?g. }

• W2410289376 abstract "Background Helminth infections, such as soil‐transmitted helminths, schistosomiasis, onchocerciasis, and lymphatic filariasis, are prevalent in many countries where human immunodeficiency virus (HIV) infection is also common. There is some evidence from observational studies that HIV and helminth co‐infection may be associated with higher viral load and lower CD4+ cell counts. Treatment of helminth infections with antihelminthics (deworming drugs) may have benefits for people living with HIV beyond simply clearance of worm infections. This is an update of a Cochrane Review published in 2009 and we have expanded it to include outcomes of anaemia and adverse events. Objectives To evaluate the effects of deworming drugs (antihelminthic therapy) on markers of HIV disease progression, anaemia, and adverse events in children and adults. Search methods In this review update, we searched online for published and unpublished studies in the Cochrane Library, MEDLINE, EMBASE, CENTRAL, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICRTP), ClinicalTrials.gov, and the WHO Global Health Library up to 29 September 2015. We also searched databases listing conference abstracts, scanned reference lists of articles, and contacted the authors of included studies. Selection criteria We searched for randomized controlled trials (RCTs) that compared antihelminthic drugs with placebo or no intervention in HIV‐positive people. Data collection and analysis Two review authors independently extracted data and assessed trials for eligibility and risk of bias. The primary outcomes were changes in HIV viral load and CD4+ cell count, and secondary outcomes were anaemia, iron deficiency, adverse events, and mortality events. We compared the effects of deworming using mean differences, risk ratios (RR), and 95% confidence intervals (CIs). We assessed the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Main results Eight trials met the inclusion criteria of this review, enrolling a total of 1612 participants. Three trials evaluated the effect of providing antihelminthics to all adults with HIV without knowledge of their helminth infection status, and five trials evaluated the effects of providing deworming drugs to HIV‐positive individuals with confirmed helminth infections. Seven trials were conducted in sub‐Saharan Africa and one in Thailand. Antihelminthics for people with unknown helminth infection status Providing antihelminthics (albendazole and praziquantel together or separately) to HIV‐positive adults with unknown helminth infection status may have a small suppressive effect on mean viral load at six weeks but the 95% CI includes the possibility of no effect (difference in mean change −0.14 log10 viral RNA/mL, 95% CI −0.35 to 0.07, P = 0.19; one trial, 166 participants, low quality evidence). Repeated dosing with deworming drugs over two years (albendazole every three months plus annual praziquantel), probably has little or no effect on mean viral load (difference in mean change 0.01 log10 viral RNA, 95% CI: −0.03 to −0.05; one trial, 917 participants, moderate quality evidence), and little or no effect on mean CD4+ count (difference in mean change 2.60 CD4+ cells/µL, 95% CI −10.15 to 15.35; P = 0.7; one trial, 917 participants, low quality evidence). Antihelminthics for people with confirmed helminth infections Treating confirmed helminth infections in HIV‐positive adults may have a small suppressive effect on mean viral load at six to 12 weeks following deworming (difference in mean change −0.13 log10 viral RNA, 95% CI −0.26 to −0.00; P = 0.04; four trials, 445 participants, low quality evidence). However, this finding is strongly influenced by a single study of praziquantel treatment for schistosomiasis. There may also be a small favourable effect on mean CD4+ cell count at 12 weeks after deworming in HIV‐positive populations with confirmed helminth infections (difference in mean change 37.86 CD4+ cells/µL, 95% CI 7.36 to 68.35; P = 0.01; three trials, 358 participants, low quality evidence). Adverse events and mortality There is no indication that antihelminthic drugs impart additional risks in HIV‐positive populations. However, adverse events were not well reported (very low quality evidence) and trials were underpowered to evaluate effects on mortality (low quality evidence). Authors' conclusions There is low quality evidence that treating confirmed helminth infections in HIV‐positive adults may have small, short‐term favourable effects on markers of HIV disease progression. Further studies are required to confirm this finding. Current evidence suggests that deworming with antihelminthics is not harmful, and this is reassuring for the routine treatment of confirmed or suspected helminth infections in people living with HIV in co‐endemic areas. Further long‐term studies are required to make confident conclusions regarding the impact of presumptively deworming all HIV‐positive individuals irrespective of helminth infection status, as the only long‐term trial to date did not demonstrate an effect." @default.
• W2410289376 created "2016-06-24" @default.
• W2410289376 creator A5038440081 @default.
• W2410289376 creator A5043790717 @default.
• W2410289376 creator A5053734994 @default.
• W2410289376 creator A5089919219 @default.
• W2410289376 date "2016-04-14" @default.
• W2410289376 modified "2023-09-27" @default.
• W2410289376 title "Antihelminthics in helminth-endemic areas: effects on HIV disease progression" @default.
• W2410289376 cites W1533706024 @default.
• W2410289376 cites W1872465200 @default.
• W2410289376 cites W1904201688 @default.
• W2410289376 cites W1933338915 @default.
• W2410289376 cites W1954177177 @default.
• W2410289376 cites W1966193770 @default.
• W2410289376 cites W1973508574 @default.
• W2410289376 cites W1976212756 @default.
• W2410289376 cites W1978141065 @default.
• W2410289376 cites W1980005248 @default.
• W2410289376 cites W1984222191 @default.
• W2410289376 cites W1986433654 @default.
• W2410289376 cites W1990239001 @default.
• W2410289376 cites W1995161323 @default.
• W2410289376 cites W1996188465 @default.
• W2410289376 cites W1997059630 @default.
• W2410289376 cites W1998711609 @default.
• W2410289376 cites W2000508319 @default.
• W2410289376 cites W2003533521 @default.
• W2410289376 cites W2009495896 @default.
• W2410289376 cites W2016367150 @default.
• W2410289376 cites W2021579239 @default.
• W2410289376 cites W2021862610 @default.
• W2410289376 cites W2024726381 @default.
• W2410289376 cites W2029124946 @default.
• W2410289376 cites W2031082988 @default.
• W2410289376 cites W2035264410 @default.
• W2410289376 cites W2036735100 @default.
• W2410289376 cites W2050349991 @default.
• W2410289376 cites W2054445248 @default.
• W2410289376 cites W2056400914 @default.
• W2410289376 cites W2060439904 @default.
• W2410289376 cites W2061544529 @default.
• W2410289376 cites W2068382969 @default.
• W2410289376 cites W2069577649 @default.
• W2410289376 cites W2072353432 @default.
• W2410289376 cites W2074269365 @default.
• W2410289376 cites W2085470246 @default.
• W2410289376 cites W2099155116 @default.
• W2410289376 cites W2100179766 @default.
• W2410289376 cites W2101848665 @default.
• W2410289376 cites W2101912413 @default.
• W2410289376 cites W2103667461 @default.
• W2410289376 cites W2107108433 @default.
• W2410289376 cites W2107328434 @default.
• W2410289376 cites W2108629958 @default.
• W2410289376 cites W2108859519 @default.
• W2410289376 cites W2110712236 @default.
• W2410289376 cites W2112762036 @default.
• W2410289376 cites W2113456373 @default.
• W2410289376 cites W2113500083 @default.
• W2410289376 cites W2120793514 @default.
• W2410289376 cites W2121229005 @default.
• W2410289376 cites W2122932058 @default.
• W2410289376 cites W2124313106 @default.
• W2410289376 cites W2134658102 @default.
• W2410289376 cites W2137034219 @default.
• W2410289376 cites W2138838217 @default.
• W2410289376 cites W2148138050 @default.
• W2410289376 cites W2149409092 @default.
• W2410289376 cites W2153089686 @default.
• W2410289376 cites W2155776788 @default.
• W2410289376 cites W2156846423 @default.
• W2410289376 cites W2165681935 @default.
• W2410289376 cites W2170138309 @default.
• W2410289376 cites W4231908565 @default.
• W2410289376 cites W4248951779 @default.
• W2410289376 doi "https://doi.org/10.1002/14651858.cd006419.pub4" @default.
• W2410289376 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4963621" @default.
• W2410289376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27075622" @default.
• W2410289376 hasPublicationYear "2016" @default.
• W2410289376 type Work @default.
• W2410289376 sameAs 2410289376 @default.
• W2410289376 citedByCount "21" @default.
• W2410289376 countsByYear W24102893762016 @default.
• W2410289376 countsByYear W24102893762017 @default.
• W2410289376 countsByYear W24102893762018 @default.
• W2410289376 countsByYear W24102893762019 @default.
• W2410289376 countsByYear W24102893762020 @default.
• W2410289376 countsByYear W24102893762021 @default.
• W2410289376 countsByYear W24102893762022 @default.
• W2410289376 countsByYear W24102893762023 @default.
• W2410289376 crossrefType "journal-article" @default.
• W2410289376 hasAuthorship W2410289376A5038440081 @default.
• W2410289376 hasAuthorship W2410289376A5043790717 @default.
• W2410289376 hasAuthorship W2410289376A5053734994 @default.
• W2410289376 hasAuthorship W2410289376A5089919219 @default.
• W2410289376 hasBestOaLocation W24102893762 @default.
• W2410289376 hasConcept C126322002 @default.
• W2410289376 hasConcept C142462285 @default.
• W2410289376 hasConcept C142724271 @default.

• next